Semaglutide for Alcohol Use Disorder
NCT05520775 on ClinicalTrials.gov · last registry update 2025-04-02
A small phase 2 — 48 participants, against a typical 110. The sponsor logged completion for 12 April 2024. Primary outcome, as filed: Change in Alcohol Consumed. semaglutide is approved in the US, but not for alcohol use disorder — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P2
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- University of North Carolina, Chapel Hill
- Sponsor type
- Other
- Enrollment
- 48
- Started
- 2022-09-02
- Primary completion
- 2024-04-12 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in Alcohol Consumed
Conditions studied
Alcohol Use Disorder · Cigarette Smoking
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.